PURPOSE: To assess the efficacy and safety of liposomal cytarabine in the treatment of de novo and relapsed leptomeningeal involvement in children with primary CNS tumours. METHODS: Data from clinical charts were entered into a database for consecutive unselected patients (n=20) from nine Spanish centres. Diagnosis of leptomeningeal involvement was confirmed by cytology, MRI and/or CT scan. The dose of liposomal cytarabine used varied from 20 to 50 mg, by age. RESULTS: There were 8 females and 12 males, mean age 7.3 years (range 8 months to 18 years). The tumours were: 10 medulloblastomas, 4 ependymomas, 3 primitive neuroectodermal tumours and 3 other tumours. Fourteen had undergone previous chemotherapy and 12 radiotherapy. Nine received concurrent chemotherapy and 2 concurrent radiotherapy. Median follow-up was 244.5 days (range 12- 869). Patients received a median of 5 doses (range 1-9) of liposomal cytarabine. A neurological response (complete or partial) was seen in 11/19 (58%) and a cytological response in 7/10 (64%). Median time to neurological progression exceeded 180 days (range 12-869). Adverse effects were reported in 11/20 patients, but none was grade IV. DISCUSSION: Liposomal cytarabine was well tolerated and efficacious in this patient group, but prospective randomised trials are needed.
PURPOSE: To assess the efficacy and safety of liposomal cytarabine in the treatment of de novo and relapsed leptomeningeal involvement in children with primary CNS tumours. METHODS: Data from clinical charts were entered into a database for consecutive unselected patients (n=20) from nine Spanish centres. Diagnosis of leptomeningeal involvement was confirmed by cytology, MRI and/or CT scan. The dose of liposomal cytarabine used varied from 20 to 50 mg, by age. RESULTS: There were 8 females and 12 males, mean age 7.3 years (range 8 months to 18 years). The tumours were: 10 medulloblastomas, 4 ependymomas, 3 primitive neuroectodermal tumours and 3 other tumours. Fourteen had undergone previous chemotherapy and 12 radiotherapy. Nine received concurrent chemotherapy and 2 concurrent radiotherapy. Median follow-up was 244.5 days (range 12- 869). Patients received a median of 5 doses (range 1-9) of liposomal cytarabine. A neurological response (complete or partial) was seen in 11/19 (58%) and a cytological response in 7/10 (64%). Median time to neurological progression exceeded 180 days (range 12-869). Adverse effects were reported in 11/20 patients, but none was grade IV. DISCUSSION: Liposomal cytarabine was well tolerated and efficacious in this patient group, but prospective randomised trials are needed.
Authors: M J Glantz; S LaFollette; K A Jaeckle; W Shapiro; L Swinnen; J R Rozental; S Phuphanich; L R Rogers; J C Gutheil; T Batchelor; D Lyter; M Chamberlain; B L Maria; C Schiffer; R Bashir; D Thomas; W Cowens; S B Howell Journal: J Clin Oncol Date: 1999-10 Impact factor: 44.544
Authors: L Bomgaars; J R Geyer; J Franklin; G Dahl; J Park; N J Winick; R Klenke; S L Berg; S M Blaney Journal: J Clin Oncol Date: 2004-10-01 Impact factor: 44.544
Authors: Martin Benesch; Petra Sovinz; Barbara Krammer; Herwig Lackner; Georg Mann; Wolfgang Schwinger; Helmut Gadner; Christian Urban Journal: J Pediatr Hematol Oncol Date: 2007-04 Impact factor: 1.289
Authors: Juan P Fusco; Eduardo Castañón; Omar E Carranza; Leire Zubiri; Patricia Martín; Jaime Espinós; Javier Rodríguez; Marta Santisteban; José M Aramendía; Ignacio Gil-Bazo Journal: J Neurooncol Date: 2013-09-15 Impact factor: 4.130